PIK3CA mutations are prognostic markers for PPC, and inhibition of the PIK3CA-related pathway may contribute to improving the prognosis of patients with PPC, including improving the efficacy of ICI therapy. This evidence concerns the gene PIK3CA and primary peritoneal carcinoma.